# Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

> **NCT03958721** · PHASE1 · COMPLETED · sponsor: **A Bapsi Chakravarthy, MD** · enrollment: 20 (actual)

## Conditions studied

- Resistant Breast Cancer
- Non-metastatic Invasive Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT03958721
- **Lead sponsor:** A Bapsi Chakravarthy, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-18
- **Primary completion:** 2023-10-26
- **Final completion:** 2023-10-26
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03958721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03958721, "Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03958721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*